However, WIN 18,446 has been used in humans and animals with minimal side effects, and use of targeted drug delivery methods to the colon as well as more specific inhibitors of ALDH1A enzyme (ALDH1A1 vs. ALDH1A2) also can be developed if this pathway is validated for IBD treatment. The gene discussed is ALDH1A1; the disease is inflammatory bowel disease.